Pegcetacoplan - CISMeF

Preferred Label : Pegcetacoplan;

NCIt definition : A pegylated peptide inhibitor of human complement components C3 and C3b, with potential use as a treatment for various diseases in which excessive complement activation plays a key role, including paroxysmal nocturnal hemoglobinuria (PNH), geographic atrophy (GA), cold agglutinin disease (CAD), and C3 glomerulopathy (C3G). Upon administration, pegcetacoplan selectively binds to C3 and C3b and inhibits their activities. This prevents complement pathway activation, and inhibits complement-mediated inflammation and cell lysis. Excessive complement activation plays a key role in various inflammatory and autoimmune diseases, and leads to tissue destruction. C3 is a key component of the complement system, and the complement system is an integral component of the innate immune response.;

UNII : TO3JYR3BOU;

CAS number : 2019171-69-6;

Drug name : Empaveli;

Molecule name : APL-2; APL 2;

NCI Metathesaurus CUI : CL1382535;

Details

Origin ID

C121135;

UMLS CUI

C5418501;

Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Pegcetacoplan (substance) [SNOMED CT concept]
- Product containing pegcetacoplan (medicinal product) [SNOMED CT concept]
- pegcetacoplan [MeSH Supplementary Concept]
- pegcetacoplan [ATC Code]
- pegcetacoplan [ATC Code]
Validated automatic mappings to BTNT
- pegcetacoplan [ATC Code]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
has_target
- Complement C3 [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients